Meta Pixel

News and Announcements

Major Biopharmaceutical Signs to Up to MedAdvisor Patient Engagement Program

  • Published July 01, 2016 4:35PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

1st July 2016, ASX Announcement

Highlights:

  • MedAdvisor is collaborating with Bristol-Myers Squibb Australia (BMS) to deliver a patient engagement and education program concerning one of its products
  • Commencing shortly the 12-month patient engagement program (PEP) is being delivered via MedAdvisor’s medication management platform
  • This agreement will generate further PEP revenue for MedAdvisor
  • Provides further strong validation for MedAdvisor’s platform from a leading global biopharmaceutical company

MedAdvisors Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce that it will be collaborating with the Australian subsidiary of leading global pharmaceutical company, Bristol-Myers Squibb Company, to deliver a new patient engagement and education program.

To view the full announcement, please click on the button below.

Capital Insights
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t

The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.

Capital Insights
Following the Billions: Where the Hyperscalers are Betting on the Future

The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.

Join over 45,000+ sophisticated investors

Join Now